Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

Waldhauer, 2008, NK cells and cancer immunosurveillance, Oncogene, 27, 5932, 10.1038/onc.2008.267 Nausch, 2008, NKG2D ligands in tumor immunity, Oncogene, 27, 5944, 10.1038/onc.2008.272 Raulet, 2006, Self-tolerance of natural killer cells, Nat Rev Immunol, 6, 520, 10.1038/nri1863 Hershkovitz, 2008, Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool, Glycobiology, 18, 28, 10.1093/glycob/cwm125 Rosental, 2011, Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44, J Immunol, 187, 5693, 10.4049/jimmunol.1102267 Hershkovitz, 2007, Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44, Biochemistry, 46, 7426, 10.1021/bi7000455 Pogge von Strandmann, 2007, Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells, Immunity, 27, 965, 10.1016/j.immuni.2007.10.010 Brandt, 2009, The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans, J Exp Med, 206, 1495, 10.1084/jem.20090681 Oppenheim, 2005, Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance, Nat Immunol, 6, 928, 10.1038/ni1239 Coudert, 2005, Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells, Blood, 106, 1711, 10.1182/blood-2005-03-0918 Groh, 2002, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, 419, 734, 10.1038/nature01112 Kaiser, 2007, Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands, Nature, 447, 482, 10.1038/nature05768 Salih, 2003, Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia, Blood, 102, 1389, 10.1182/blood-2003-01-0019 Salih, 2008, Soluble NKG2D ligands: prevalence, release, and functional impact, Front Biosci, 13, 3448, 10.2741/2939 Paschen, 2009, Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B, Clin Cancer Res, 15, 5208, 10.1158/1078-0432.CCR-09-0886 Li, 2009, Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis, Cancer Immunol Immunother, 58, 641, 10.1007/s00262-008-0585-3 Hilpert, 2012, Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses, J Immunol, 189, 1360, 10.4049/jimmunol.1200796 Tursz, 1982, Low natural killer cell activity in patients with malignant lymphoma, Cancer, 50, 2333, 10.1002/1097-0142(19821201)50:11<2333::AID-CNCR2820501119>3.0.CO;2-W Konjevic, 1999, The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease, Br J Haematol, 104, 144, 10.1046/j.1365-2141.1999.01129.x Lanier, 2008, Up on the tightrope: natural killer cell activation and inhibition, Nat Immunol, 9, 495, 10.1038/ni1581 Foyil, 2010, Anti-CD30 Antibodies for Hodgkin lymphoma, Curr Hematol Malig Rep, 5, 140, 10.1007/s11899-010-0053-y Eichenauer, 2008, Hodgkin's lymphoma: current treatment strategies and novel approaches, Expert Rev Hematol, 1, 63, 10.1586/17474086.1.1.63 Steidl, 2011, Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment, J Clin Oncol, 29, 1812, 10.1200/JCO.2010.32.8401 Van den Berg, 2000, Frequent lack of translation of antigen presentation-associated molecules MHC class I, CD1a and Beta(2)-microglobulin in Reed-Sternberg cells, Int J Cancer, 86, 548, 10.1002/(SICI)1097-0215(20000515)86:4<548::AID-IJC17>3.0.CO;2-A Krockenberger, 2008, Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D, J Immunol, 180, 7338, 10.4049/jimmunol.180.11.7338 Mittelbronn, 2011, Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression, Acta Neuropathol, 122, 353, 10.1007/s00401-011-0858-3 Hessa, 2011, Protein targeting and degradation are coupled for elimination of mislocalized proteins, Nature, 475, 394, 10.1038/nature10181 Jiang, 2011, Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase, Mol Cell, 43, 33, 10.1016/j.molcel.2011.04.028 Sasaki, 2007, HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53, Genes Dev, 21, 848, 10.1101/gad.1534107 Yurchenko, 2010, Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate, Exp Oncol, 32, 214 Arndt, 1999, A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors, Blood, 94, 2562, 10.1182/blood.V94.8.2562.420k20_2562_2568 Pisegna, 2002, Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells, J Immunol, 169, 68, 10.4049/jimmunol.169.1.68 Zocchi, 2012, High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas, Blood, 119, 1479, 10.1182/blood-2011-07-370841 Guerra, 2008, NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy, Immunity, 28, 571, 10.1016/j.immuni.2008.02.016 Nückel, 2010, The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia, Leukemia, 24, 1152, 10.1038/leu.2010.74 Fauriat, 2007, Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction, Blood, 109, 323, 10.1182/blood-2005-08-027979 Mamessier, 2011, Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition, Cancer Res, 71, 6621, 10.1158/0008-5472.CAN-11-0792 Delahaye, 2011, Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors, Nat Med, 17, 700, 10.1038/nm.2366 Mamessier, 2011, Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity, J Clin Invest, 121, 3609, 10.1172/JCI45816 Hartmann, 1997, Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody, Blood, 89, 2042, 10.1182/blood.V89.6.2042 Kennedy, 2006, Deciphering CD30 ligand biology and its role in humoral immunity, Immunology, 118, 143, 10.1111/j.1365-2567.2006.02354.x Lanier, 2003, Natural killer cell receptor signaling, Curr Opin Immunol, 15, 308, 10.1016/S0952-7915(03)00039-6 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, 6, 443, 10.1038/74704 Clynes, 1998, Fc receptors are required in passive and active immunity to melanoma, Proc Natl Acad Sci USA, 95, 652, 10.1073/pnas.95.2.652 North, 2007, Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation, J Immunol, 178, 85, 10.4049/jimmunol.178.1.85 Brenner, 2010, Requirements for control of B-cell lymphoma by NK cells, Eur J Immunol, 40, 494, 10.1002/eji.200939937 Younes, 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 30, 2183, 10.1200/JCO.2011.38.0410 Pörtner, 2012, T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16, Cancer Immunol Immunother, 61, 1869, 10.1007/s00262-012-1339-9 Terme, 2008, Natural killer cell-directed therapies: moving from unexpected results to successful strategies, Nat Immunol, 9, 486, 10.1038/ni1580 von Strandmann, 2006, A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo, Blood, 107, 1955, 10.1182/blood-2005-05-2177